Questions for the Record

From Science Lab to Medicine Cabinet: How China is Cornering the Market on our Medicines

3/18/2026

Representative Darin LaHood – District 16

Witness – Mr. Patrick Cashman

1. From your perspective, how important is the overall policy environment in determining where companies conduct research, invest in new therapies, and launch clinical trials? And as Congress debates different approaches to drug pricing, what should public policy makers keep in mind to ensure we are not unintentionally pushing innovation, investment, or clinical development activity outside the United States?

Answer – Mr. Patrick Cashman

"The policy environment you describe — one that supports research investment, clinical development, and the domestic launch of new therapies — is genuinely important to the health of the American pharmaceutical industry, and your concern about unintended consequences from drug pricing legislation is well founded.

USAntibiotics operates in a different part of that ecosystem. We manufacture a generic antibiotic that has been on the market for decades. Our work does not involve drug discovery, clinical trials, or new therapy development. The policy questions most directly relevant to our business are not about innovation incentives but about manufacturing standards and their equal enforcement, ensuring that the FDA oversight requirements that domestic manufacturers meet every day are applied with the same rigor to foreign facilities supplying the American market.

To the extent your question speaks to the broader principle that policy should not inadvertently drive critical pharmaceutical activity offshore, we share that concern entirely. In our case, the activity at risk is not research but the physical production of medicines that Americans depend on. The same logic that counsels against policies that push R&D overseas applies to policies, or the absence of policies, that have already pushed generic drug manufacturing there. We would welcome the opportunity to discuss the manufacturing dimension of that challenge with your office in greater detail."